Exenatide once weekly improved glycaemic control, cardiometabolic risk factors and a composite index of an HbA1c < 7%, without weight gain or hypoglycaemia, over 52 weeks

por Bergenstal, R M, Li, Y, Porter, T K Booker, Weaver, C, Han, J
Publicado 2013

New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3)...

por Bolli, G B, Riddle, M C, Bergenstal, R M, Ziemen, M, Sestakauskas, K, Goyeau, H, Home, P D
Publicado 2015

Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaem...

por Yki‐Järvinen, H., Bergenstal, R. M., Bolli, G. B., Ziemen, M., Wardecki, M., Muehlen‐Bartmer, I., Maroccia, M., Riddle, M. C.
Publicado 2015

Randomized, double‐blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGI...

por Bergenstal, R. M., Lunt, H., Franek, E., Travert, F., Mou, J., Qu, Y., Antalis, C. J., Hartman, M. L., Rosilio, M., Jacober, S. J., Bastyr, E. J.
Publicado 2016

LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) t...

por Daniels, G H, Hegedüs, L, Marso, S P, Nauck, M A, Zinman, B, Bergenstal, R M, Mann, J F E, Derving Karsbøl, J, Moses, A C, Buse, J B, Tuttle, R M
Publicado 2015